The information on this page was produced at the start of the COVID-19 pandemic.
The vast majority of the contents of this page has been archived. If you require access to any of the material that was previously held on this page please contact a member of the Medicines Optimisation team at BLMKCCG.Bedsmeds@nhs.net
Covid Medicines Delivery Unit (CMDU) *NEW* *LINKS UPDATED 13/06/2022*
The NHS has introduced the intravenous neutralising monoclonal antibody (nMab) Sotrovimab, the oral antivirals Molnupiravir and Paxlovid® and the intravenous antiviral Remdesvir for the treatment of non-hospitalised patients with coronavirus (COVID-19) infection:
-whom are symptomatic, showing no signs of clinical improvement and their symptom onset is predominantly within 5 days
-COVID-19 infection confirmed with a positive PCR test or lateral flow test reported to gov.uk or via 119
-they fall within the ‘highest risk’ group as defined in the national clinical policy (see below)
These treatments are accessible through the CMDU multidisciplinary clinical triage team, who receive completed referral forms, assess and prescribe, if clinically indicated and in line with the national clinical policy.
These treatments should NOT be prescribed by general practitioners within primary care or specialist teams from within secondary care/ community providers.
If a patient is identified as meeting the clinical policy criteria they should be referred into the CMDU clinical triage team for review via email (see referral forms below).
These treatments are currently supplied and administered (if intravenous) via HOSPITAL ONLY and cannot be dispensed via local community pharmacies.
The two designated CMDU sites for supply and administration are: Bedford Site, Bedford Hospital Foundation NHS Trust and Milton Keynes University Hospital NHS Trust.
Please see below for further information on the CMDU
- CMDU clinical policy Updated June 2022
- BLMK COVID Medicine Delivery Unit (CDMU) overview for GPs
- CMDU Referral Proforma June 2022